NOUVASANT PHARMhealth LTD.[Jiangsu,China] Business Type: Manufacturer , Trade Company , Agent , Distributor/WholesalerMain Mark: Africa , Americas , Asia , Caribbean , East Europe , Europe , Middle East , North Europe , Oceania , Other Markets , West Europe , WorldwideExporter: 71% - 80%Certs: FDADescription: Orlistat Capsules 120mg,Orlistat Capsules,Orlistat
Orlistat Capsules 120mg are indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI ≥ 28 kg/m2) with associated risk factors.
Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.
If you are a distributor, please inquire with us about product registration, importing and/or marketing our products in your country or region.
If you are a consumer, don't hesitate to contact us about more information for this product.